“Pre-clinical studies in animals as well as the first data from clinical studies show that hydroxychloroquine kills the coronavirus,” Mr. Narasimhan said in an interview with Swiss newspaper SonntagsZeitung.
Novartis is developing treatment protocols for clinical use of HCQ but Mr. Narasimhan said it’s premature to definitely stand by the findings.
The company is donating 130 million doses of the drug and supporting clinical trials before the FDA approves HCQ to treat COVID-19.
Novartis is also studying three of its drugs for their effect on complications related to COVID-19.
More articles on devices:
6 industry layoffs, furloughs for physician leaders to know
Dr. Neal ElAttrache defends orthopedic surgeries performed during COVID-19 crisis
‘The patients are deferred; they’re not going away,’ says Life Spine CEO on coronavirus
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.